Rallybio Corp SEC filings RLYB
Rallybio Corp has 308 filings in SEC EDGAR's recent list, going back to May 7, 2018. Its latest annual report, Form 10-K, was filed on Mar 16, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Oct 27, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (officer or director change, shareholder vote results, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Shareholder vote results, Other events
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Other events
|
Oct 26, 2026 | Oct 25, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 9, 2026 | Sep 8, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Change in control, Officer or director change, Regulation FD disclosure
|
Jun 1, 2026 | May 31, 2026 |
| 8-K |
Current report
Agreement ended
|
May 4, 2026 | May 3, 2026 |
| 8-K |
Current report
Officer or director change
|
Mar 31, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Change in control, Officer or director change, Regulation FD disclosure
|
Mar 2, 2026 | Mar 1, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Jan 29, 2026 | Jan 26, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 6, 2025 | Nov 6, 2025 |
| 8-K |
Current report
Listing notice
|
Aug 29, 2025 | Aug 26, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 7, 2025 | Aug 7, 2025 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Other events
|
Jul 8, 2025 | Jul 8, 2025 |
| 8-K |
Current report
Officer or director change
|
Jun 27, 2025 | Jun 25, 2025 |
| 8-K |
Current report
Shareholder vote results
|
May 16, 2025 | May 13, 2025 |
| 8-K |
Current report
Results of operations
|
May 8, 2025 | May 8, 2025 |
| 8-K |
Current report
Other events
|
Apr 8, 2025 | Apr 8, 2025 |
| 8-K |
Current report
Other events
|
Mar 13, 2025 | Mar 13, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 13, 2025 | Mar 13, 2025 |
| 8-K |
Current report
Listing notice
|
Feb 25, 2025 | Feb 24, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 7, 2024 | Nov 7, 2024 |
| 8-K |
Current report
Officer or director change
|
Sep 17, 2024 | Sep 16, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 8, 2024 | Aug 8, 2024 |
| 8-K |
Current report
Officer or director change
|
Jul 23, 2024 | Jul 23, 2024 |
| 8-K |
Current report
Shareholder vote results
|
May 21, 2024 | May 15, 2024 |
| 8-K |
Current report
Results of operations
|
May 9, 2024 | May 9, 2024 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Apr 10, 2024 | Apr 9, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 12, 2024 | Mar 12, 2024 |
| 8-K |
Current report
Results of operations, Exit or restructuring costs
|
Feb 6, 2024 | Feb 6, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 20, 2023 | Dec 20, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 9, 2023 | Nov 9, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 8, 2023 | Aug 8, 2023 |
| 8-K |
Current report
Officer or director change
|
Jun 29, 2023 | Jun 28, 2023 |
| 8-K |
Current report
Shareholder vote results
|
May 22, 2023 | May 17, 2023 |
| 8-K |
Current report
Results of operations
|
May 9, 2023 | May 9, 2023 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Mar 6, 2023 | Mar 6, 2023 |
| 8-K |
Current report
Officer or director change
|
Jan 31, 2023 | Jan 31, 2023 |
| 8-K |
Current report
Other events
|
Dec 1, 2022 | Nov 28, 2022 |
| 8-K |
Current report
Material agreement, Other events
|
Nov 14, 2022 | Nov 10, 2022 |
| 8-K |
Current report
Results of operations
|
Nov 7, 2022 | Nov 7, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 28, 2022 | Sep 28, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 8, 2022 | Aug 8, 2022 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Aug 2, 2022 | Aug 1, 2022 |
| 8-K |
Current report
Officer or director change
|
Jun 2, 2022 | Jun 2, 2022 |
| 8-K |
Current report
Shareholder vote results
|
May 27, 2022 | May 24, 2022 |
| 8-K |
Current report
Material agreement, Results of operations, Other events
|
May 10, 2022 | May 5, 2022 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Apr 4, 2022 | Apr 1, 2022 |
| 8-K |
Current report
Results of operations
|
Mar 15, 2022 | Mar 15, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 7, 2022 | Mar 7, 2022 |
| 8-K |
Current report
Results of operations
|
Nov 10, 2021 | Nov 10, 2021 |
| 8-K |
Current report
Results of operations
|
Sep 9, 2021 | Sep 9, 2021 |
| 8-K |
Current report
Material agreement, Change to shareholder rights, Bylaw or fiscal year change
|
Aug 2, 2021 | Jul 28, 2021 |
Showing 51 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RLYB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New Haven, CT
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1739410
- Former names
- Rallybio Holdings, LLC (until Jun 7, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.